Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma

Clinical Therapeutics

Volumn 38, Issue 7, 2016, Pages 1589-1599

  Pectasides, Eirini ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

esophageal adenocarcinoma; Gastric adenocarcinoma; genomics; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR RECEPTOR; TRASTUZUMAB;

ANTIANGIOGENIC THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL ADENOCARCINOMA; GENOMICS; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; REVIEW; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; GENETICS; HUMAN GENOME; PERSONALIZED MEDICINE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; GENOME, HUMAN; HUMANS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84962106251     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.03.016     Document Type: Review

References (49)

1. 1 Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cance 136 (2015), E359–E386, 10.1002/ijc.29210.
2. 2 Pohl, H., Sirovich, B., Welch, H.G., Esophageal adenocarcinoma incidence: are we reaching the peak?. Cancer Epidemiol Biomarkers Prev 19 (2010), 1468–1470, 10.1158/1055-9965.EPI-10-0012.
3. 3 Deng, N., Goh, L.K., Wang, H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61 (2012), 673–684, 10.1136/gutjnl-2011-301839.
4. 4 Cunningham, D., Starling, N., Rao, S., et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med 358 (2008), 36–46, 10.1056/NEJMoa073149.
5. 5 Shah, M.A., Janjigian, Y.Y., Stoller, R., et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Onco 33:33 (2015), 3874–3879, 10.1200/JCO.2015.60.7465.
6. 6 Al-Batran, S.E., Hartmann, J.T., Probst, S., et al. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Onco 26 (2008), 1435–1442, 10.1200/JCO.2007.13.9378.
7. 7 The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:7517 (2014), 202–209, 10.1038/nature13480.
8. 8 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 (2015), 2509–2520, 10.1056/NEJMoa1500596.
9. 9 Ali, S.M., Sanford, E.M., Klempner, S.J., et al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist 20 (2015), 499–507, 10.1634/theoncologist.2014-0378.
10. 10 Dulak, A.M., Stojanov, P., Peng, S., et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Na Genet 45 (2013), 478–486, 10.1038/ng.2591.
11. 11 Wang, K., Johnson, A., Ali, S.M., et al. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist 20 (2015), 1132–1139, 10.1634/theoncologist.2015-0156.
12. 12 Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:4785 (1987), 177–182.
13. 13 Seshadri, R., Firgaira, F.A., Horsfall, D.J., McCaul, K., Setlur, V., Kitchen, P., Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Onco 11 (1993), 1936–1942.
14. 14 Janjigian, Y.Y., Werner, D., Pauligk, C., et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. An Oncol 23 (2012), 2656–2662, 10.1093/annonc/mds104.
15. 15 Tanner, M., Hollmén, M., Junttila, T.T., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16 (2005), 273–278, 10.1093/annonc/mdi064.
16. 16 Slamon, D.J., Leyland-Jones, B., Shak, S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001), 783–792, 10.1056/NEJM200103153441101.
17. 17 Bang, Y.-J., Van Cutsem, E., Feyereislova, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:9742 (2010), 687–697, 10.1016/S0140-6736(10)61121-X.
18. 18 Iqbal, S., Goldman, B., Fenoglio-Preiser, C.M., et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22 (2011), 2610–2615, 10.1093/annonc/mdr021.
19. 19 Hecht, J.R., Bang, Y.-J., Qin, S.K., et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC- A Randomized Phase III Trial. J Clin Onco 34 (2016), 443–451, 10.1200/JCO.2015.62.6598.
20. 20 Satoh, T., Xu, R.-H., Chung, H.-C., et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Onco 32:19 (2014), 2039–2049, 10.1200/JCO.2013.53.6136.
21. 21 Gomez-Martin, C., Plaza, J.C., Pazo-Cid, R., et al. Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. J Clin Onco 31 (2013), 4445–4452, 10.1200/JCO.2013.48.9070.
22. 22 Kim, M.A., Lee, H.S., Lee, H.E., Jeon, Y.K., Yang, H.K., Kim, W.H., EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52 (2008), 738–746, 10.1111/j.1365-2559.2008.03021.x.
23. 23 Langer, R., Rahden Von, B.H.A., Nahrig, J., et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Patho 59 (2006), 631–634, 10.1136/jcp.2005.034298.
24. 24 Lordick, F., Kang, Y.-K., Chung, H.-C., et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14 (2013), 490–499, 10.1016/S1470-2045(13)70102-5.
25. 25 Lordick, F., Kang, Y.-K., Salman, P., et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. ASC Meetin Abst, 31(15 suppl), 2013, 4021.
26. 26 Waddell, T., Chau, I., Cunningham, D., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14:6 (2013), 481–489, 10.1016/S1470-2045(13)70096-2.
27. 27 Ferry, D.R., Anderson, M., Beddard, K., et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. C i Cance R 13 (2007), 5869–5875, 10.1158/1078-0432.CCR-06-1970.
28. 28 Janmaat, M.L., Gallegos-Ruiz, M.I., Rodriguez, J.A., et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Onco 24 (2006), 1612–1619, 10.1200/JCO.2005.03.4900.
29. 29 Dragovich, T., McCoy, S., Fenoglio-Preiser, C.M., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Onco 24 (2006), 4922–4927, 10.1200/JCO.2006.07.1316.
30. 30 Zhang, L., Yang, J., Cai, J., et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep, 3, 2013 http://dx.doi.org/10.1038/srep02992.
31. 31 Su, X., Zhan, P., Gavine, P.R., et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cance 110 (2014), 967–975, 10.1038/bjc.2013.802.
32. 32 Bang, Y.-J., Van Cutsem, E., Mansoor, W., et al. A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. ASC Meetin Abst, 33(15 suppl), 2015, 4014.
33. 33 Nakajima, M., Sawada, H., Yamada, Y., et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85 (1999), 1894–1902.
34. 34 Drebber, U., Baldus, S.E., Nolden, B., et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19 (2008), 1477–1483.
35. 35 Janjigian, Y.Y., Tang, L.H., Coit, D.G., et al. MET expression and amplification in patients with localized gastric cancer. Cancer. Epidemiol. Biomarkers. Prev 20 (2011), 1021–1027, 10.1158/1055-9965.EPI-10-1080.
36. 36 Iveson, T., Donehower, R.C., Davidenko, I., et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 15 (2014), 1007–1018, 10.1016/S1470-2045(14)70023-3.
37. 37 Cunningham, D., Tebbutt, N.C., Davidenko, I., et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. ASC Meetin Abstract, 33(15 suppl), 2015, 4000.
38. 38 Shah, M.A., Bang, Y.-J., Lordick, F., et al. METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). ASC Meetin Abst, 33(15 suppl), 2015, 4012.
39. 39 Shah, M.A., Cho, J.Y., Huat, I.T.B., et al. Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). ASC Meetin Abst, 33(3 suppl), 2015, 2.
40. 40 Kwak, E.L., LoRusso, P., Hamid, O., et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. ASC Meetin Abst, 33(3 suppl), 2015, 1.
41. 41 Ohtsu, A., Shah, M.A., Van Cutsem, E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Onco 29:30 (2011), 3968–3976, 10.1200/JCO.2011.36.2236.
42. 42 Van Cutsem, E., de Haas, S., Kang, Y.-K., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Onco 30:17 (2012), 2119–2127, 10.1200/JCO.2011.39.9824.
43. 43 Fuchs, C.S., Tomasek, J., Yong, C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:9911 (2014), 31–39, 10.1016/S0140-6736(13)61719-5.
44. 44 Wilke, H., Muro, K., Van Cutsem, E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235, 10.1016/S1470-2045(14)70420-6.
45. 45 Yoon, H.H., Bendell, J.C., Braiteh, F.S., et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. . ASCO Meeting Abstr, 32(15 suppl), 2014, 4004.
46. 46 Kim, J., Fox, C., Peng, S., et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Inves 124 (2014), 5145–5158, 10.1172/JCI75200.
47. 47 Kwak, E.L., Ahronian, L.G., Siravegna, G., et al. Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cance Discov 5 (2015), 1271–1281, 10.1158/2159-8290.CD-15-0748.
48. 48 Kopetz, S., Desai, J., Chan, E., et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Onco 33 (2015), 4032–4038, 10.1200/JCO.2015.63.2497.
49. 49 Corcoran, R.B., Atreya, C.E., Falchook, G.S., et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Onco 33 (2015), 4023–4031, 10.1200/JCO.2015.63.2471.